UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045185
Receipt number R000051620
Scientific Title "ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS: A Preliminary Randomized Controlled Clinical Trial
Date of disclosure of the study information 2021/08/18
Last modified on 2021/08/18 14:15:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS:
A Preliminary Randomized Controlled Clinical Trial

Acronym

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS:
A Preliminary Randomized Controlled Clinical Trial

Scientific Title

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS:
A Preliminary Randomized Controlled Clinical Trial

Scientific Title:Acronym

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS:
A Preliminary Randomized Controlled Clinical Trial

Region

Asia(except Japan)


Condition

Condition

olfactory disorder in COVID-19

Classification by specialty

Medicine in general Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the clinical presentation of olfactory disorders in COVID-19 based on the alcohol sniff test (AST) and the intravenous olfaction test (IOT) and the effectiveness of the nasal therapy protocol as an adjunct to standard therapy in COVID-19 patients with olfactory disorders

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

improvement of olfactory disorders both subjective (visual analog score) and objective by Alcohol sniff test and Intravenous olfaction test results after treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

COVID standar Therapy for 2 weeks

Interventions/Control_2

COVID standar Therapy and nasal treatment (mometasone nasal spray 2dd2 spray, normosaline nasal irrigation 2dd30 cc both nostrils, oxymethazolin 0,5% nasa spray 1dd2 spray before bedtime, aromatic vaporub 1dd1 on neck and chest before bedtime) for 2 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

50 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Confirmed Sars-COV2 PCR positive with mild or moderate symptomps
2. Impaired Alcohol Swab test result
3. Cooperative

Key exclusion criteria

1. Cognitive and conciousness impairment
2. Severe dyspnea and unstable vital sign
3. History of olfactory and taste disturbance before COVID
4. History of chronic rhinosinusitis and severe head trauma
5. History of routine use of steroid intranasal, decongestan before COVID-19
6. History of skin and vascular problem

Target sample size

24


Research contact person

Name of lead principal investigator

1st name indra
Middle name parmaditya
Last name pamungkas

Organization

ORL-HNS Departement CIpto Mangunkusumo General Hospital

Division name

Oncology-Rhinology

Zip code

10430

Address

Jl Diponegoro 71 Senen Central Jakarta

TEL

6281314319179

Email

indraparmaditya@gmail.com


Public contact

Name of contact person

1st name indra
Middle name parmaditya
Last name pamungkas

Organization

ORL-HNS Departement CIpto Mangunkusumo General Hospital

Division name

Oncology-Rhinology

Zip code

10430

Address

Jl Diponegoro 71 Senen Central Jakarta

TEL

6281314319179

Homepage URL


Email

indraparmaditya@gmail.com


Sponsor or person

Institute

there were no sponsors available

Institute

Department

Personal name



Funding Source

Organization

Rhinology division ORL-HNS Department Cipto Mangunkusumo General Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethics commitee of the faculty of medicine, University of Indonesia- Cipto Mangunkusumo Hospital

Address

University Indonesia Faculty of Medicine Building , jl salemba raya No 6 Jakarta 10430

Tel

62213912477

Email

humas@fk.ui.ac.id


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

university of Indonesia


Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

24

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 06 Month 01 Day

Date of IRB

2020 Year 06 Month 15 Day

Anticipated trial start date

2020 Year 08 Month 01 Day

Last follow-up date

2020 Year 11 Month 03 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 08 Month 18 Day

Last modified on

2021 Year 08 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051620


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name